ANGPTL3 and atherosclerosis: Both in Ldlr−/− mice treated with antisense oligonucleotides (ASO) targeting Angptl3 and in APOE*3Leiden.CETP mice treated with an antibody against ANGPTL3 (evinacumab), hypercholesterolemia, hypertriglyceridemia and atherosclerosis were significantly decreased (271, 272).